See more : Yibin Tianyuan Group Co., Ltd. (002386.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Lexeo Therapeutics, Inc. Common Stock (LXEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexeo Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Musk Metals Corp. (MUSK.CN) Income Statement Analysis – Financial Results
- The Colonial Motor Company Limited (CMO.NZ) Income Statement Analysis – Financial Results
- WISeKey International Holding AG (WIHN.SW) Income Statement Analysis – Financial Results
- Beard Co. (The) (BRCOQ) Income Statement Analysis – Financial Results
- Glencore plc (GLEN.L) Income Statement Analysis – Financial Results
Lexeo Therapeutics, Inc. Common Stock (LXEO)
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 654.00K | 1.66M | 518.48K |
| Cost of Revenue | 1.84M | 1.15M | 13.41K | 0.00 |
| Gross Profit | -1.84M | -491.00K | 1.64M | 518.48K |
| Gross Profit Ratio | 0.00% | -75.08% | 99.19% | 100.00% |
| Research & Development | 53.13M | 49.16M | 45.12M | 4.32M |
| General & Administrative | 15.38M | 12.00M | 7.17M | 787.50K |
| Selling & Marketing | -1.84M | 0.00 | 0.00 | 0.00 |
| SG&A | 13.54M | 12.00M | 7.17M | 787.50K |
| Other Expenses | 0.00 | -2.00K | -155.00 | 4.24K |
| Operating Expenses | 66.67M | 61.16M | 52.29M | 5.11M |
| Cost & Expenses | 68.51M | 61.16M | 52.29M | 5.11M |
| Interest Income | 2.87M | 1.33M | 15.00K | 0.00 |
| Interest Expense | 205.00K | 91.00K | 0.00 | 147.15K |
| Depreciation & Amortization | 1.84M | 1.15M | 13.41K | 4.24K |
| EBITDA | -66.67M | -58.04M | -50.62M | -4.58M |
| EBITDA Ratio | 0.00% | -8,874.77% | -3,054.25% | -884.04% |
| Operating Income | -68.51M | -60.51M | -50.64M | -4.59M |
| Operating Income Ratio | 0.00% | -9,252.14% | -3,055.94% | -884.86% |
| Total Other Income/Expenses | 2.12M | 1.23M | 15.00K | -565.00K |
| Income Before Tax | -66.39M | -59.28M | -50.62M | -5.15M |
| Income Before Tax Ratio | 0.00% | -9,063.76% | -3,055.04% | -993.83% |
| Income Tax Expense | 0.00 | 89.00K | -155.00 | 147.15K |
| Net Income | -66.39M | -59.28M | -50.62M | -5.15M |
| Net Income Ratio | 0.00% | -9,063.76% | -3,055.04% | -993.83% |
| EPS | -2.49 | -2.40 | -2.05 | -0.21 |
| EPS Diluted | -2.49 | -2.40 | -2.05 | -0.21 |
| Weighted Avg Shares Out | 26.65M | 24.67M | 24.67M | 24.67M |
| Weighted Avg Shares Out (Dil) | 26.65M | 24.67M | 24.67M | 24.67M |
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO
Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range
Lexeo Therapeutics Proposes Terms For $126 Million IPO
Lexeo Therapeutics Starts $100 Million U.S. IPO Effort
Source: https://incomestatements.info
Category: Stock Reports